Alan List, MD, completed his medical degree at the University of Pennsylvania College of Medicine. He further obtained his residency in internal medicine at Good Samaritan Medical Center, Phoenix, and his oncology and hematology fellowships at Vanderbilt University Medical Center, Nashville. Dr List is currently the President and CEO of the Moffitt Cancer Center, and is a Professor in the Department of Oncologic Sciences at the College of Medicine, University of South Florida in Tampa.
Dr List is a board member at the National Board of Medical Examiners and the American Board of Internal Medicine (ABIM). He is also a member several medical societies including the American Society of Clinical Oncology, the American Society of Hematology and the American Association for Cancer Research.
Speaking on myelodysplastic syndromes
Dr List’s research focuses on the development of effective treatments for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). He pioneered the treatment for MDS and multiple myeloma with the development of lenalidomide. His work allowed patients with MDS to be treated as outpatients with oral agents. Dr List has authored close to 300 peer-reviewed articles, and he authored the Clinician’s Manual on Myelodysplastic Syndromes in 2008.